Our Mission

A handful of stem cell transplants proved HIV can be cured. SHIELD HIV exists to learn how — at the level of specific donor T cells — and to turn that knowledge into a therapy that does not require a transplant.

Those cases prove cure is possible-but transplant is too toxic, rare, and complex to offer to the roughly 40 million people living with HIV worldwide. SHIELD HIV asks a practical question: What did the donor immune system actually do to erase the HIV reservoir-and can we copy that with targeted T-cell therapy?

The Hypothesis

“We hypothesize that allogeneic T cell responses targeting minor antigens mediate HIV cure.”

After a donor stem cell transplant, donor T cells recognize small differences between donor and recipient cells (minor histocompatibility antigens). In cancer, that is the “graft-versus-leukemia” effect. The team’s prior work in Mauritian cynomolgus macaques showed a similar graft-versus-reservoir effect: allogeneic immunity can purge latent virus, first from blood, then from peripheral lymph nodes, and finally from the mesenteric lymph nodes that drain the gut.

Pathway to Cure

Map the cure
Donor T-cell receptors and minor antigens linked to reservoir clearance
Prove it works
T cells carrying those receptors recuce or eliminate virus in preclinical models
Clinical-trial design
Work with transpiant specialists at OHSU toward a future trial
A cure without transplant
Off-the-shelf or engineered allogeneic T-cell therapies for HIV cure

Lead Investigators

Lishomwa (Lish) Ndhlovu, MD, PhD Herbert J. and Ann L. Siegel Distinguished Professor, Professor of Immunology in Medicine
Jonah B. Sacha, PhD, Professor and Chief, Division of Pathobiology and Immunology, Oregon National Primate Research Center

NIH Merit Award Grant #R37AI189285
TRANSLATE